Tim Friede's snakebite research aims to create universal antivenom

Tim Friede, a 58-year-old window cleaner from Wisconsin, has intentionally subjected himself to 200 snakebites over nearly 20 years to build immunity that could lead to a universal antivenom. Friede stated, "I understood it was dangerous but people are dying from snakebites and I was pissed at that. I couldn’t get that out of my head. I put my ass on the line and I’m glad I did." His efforts are now being harnessed by Centivax, a California vaccine company, which aims to produce a broad antivenom using antibodies developed from Friede's unique immunity.

The urgency for such a solution is highlighted by the rising number of snakebite incidents, exacerbated by climate change, which is increasing human-snake encounters. Currently, snakebites cause approximately 138,000 deaths and 400,000 disabilities annually, predominantly affecting poorer populations in developing countries. Jacob Glanville, CEO of Centivax, praised Friede's work, noting that his antibodies can neutralize toxins from 19 snake species, including some of the most lethal.

A trial for this antivenom is scheduled to take place on pets in Australia this year, marking a significant step towards potential human application. Friede’s journey, which included brushes with death and severe injuries, underscores the lengths he has gone to in pursuit of a solution for snakebite victims. He expressed, "I wanted to make sure this all wasn’t in vain... I wanted to do it for humanity, for people who are the brokest people on the planet."

Power Read: Friede's groundbreaking work positions him and Centivax at the forefront of a critical public health challenge, potentially granting them significant leverage in the biopharmaceutical sector. As climate change continues to increase snakebite incidents, the demand for effective antivenom solutions will rise, placing Friede's research in a strategic position to attract funding and partnerships. However, the challenge remains to secure the necessary resources and logistics to deliver this antivenom to the most affected populations, especially as international aid budgets face cuts.

What to watch: The upcoming trial of the antivenom on pets in Australia will be a key indicator of its viability for human use.